RxDoctor Payments Data

Silvana Bucur, MD

Medical Oncology · Meridian, IDNPI 1326140039

Payments from drug & device makers

What this record shows

This record is dominated by education: $161 of the $262 with a category attached, or 61.4%. 5 manufacturers reported payments, led by Clovis Oncology, Inc. at 40.4% of the total. Reporting peaked in 2019 at $132 and has fallen 67.2% since, to $43 in 2025.

$262in general payments, 2019–2025

Across 6 payments — averaging $43.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Clovis Oncology, Inc.$106
  • Intuitive Surgical$75
  • AstraZeneca$43
  • Johnson & Johnson$26
  • Gilead$12
$191,998in research payments, 2019–2025

Across 26 payments — averaging $7384.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$192K

What the payments were for

  • Food & beverage$10139%
  • Education$16161%

General payments by program year

19
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few medical oncology providers in Idahoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$46,269
Medicare patients
232
Services billed
513

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate34$547,468
ImbruvicaIbrutinib34$531,398
IbrancePalbociclib28$430,549
VenclextaVenetoclax21$274,371
RevlimidLenalidomide19$196,758
CalquenceAcalabrutinib Maleate12$46,554
EliquisApixaban13$13,786
XareltoRivaroxaban24$12,789
Abiraterone Acetate25$4,781
Acyclovir61$3,230
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen56$2,168
Tamoxifen Citrate57$2,040
Imatinib Mesylate12$1,970
Letrozole84$1,954
Exemestane20$1,834

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$43$46,55412 claims
Johnson & JohnsonXarelto$26$12,78924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few medical oncology providers in Idahoon file to place this against a meaningful peer group, so we don't.

Other medical oncology in Meridian

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →